# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Shagun Singh maintains Zynex (NASDAQ:ZYXI) with a Outperform and raises the price target from $13 to $15.
HC Wainwright & Co. analyst Yi Chen maintains Zynex (NASDAQ:ZYXI) with a Buy and raises the price target from $20 to $21.
Zynex (NASDAQ:ZYXI) reported quarterly earnings of $0.040 per share which missed the analyst consensus estimate of $0.170 by 76...
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...
Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive m...